The Longevity Podcast: Alzheimer's and Brain Health Research
Alzheimer's Drug Safety: Why Blood Thinner Exclusions Matter
Send us Fan Mail A letter in JPAD argues that a reported safety advantage for an anti-amyloid antibody drug, in a European-label subgroup of its phase 3 trial, may largely reflect excluding patients on blood thinners. About one in four people with Alzheimer's take those medicines in real-world data, so the subgroup findings may not apply in everyday practice. Source: Ijaz A, Mohyudin G, The generalizability gap: anticoagulant exclusions and the "Enhanced Safety" of donanemab in the EU-eligible population, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100628 (CC BY-NC-ND 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
